Conduit Pharmaceuticals Gross Profit

The latest gross profit for CDT is $1.1B as of June 2026. That compares with $1.4B in the prior-year period — down 22.9% year over year. That is above the sector sector average of $760M. Investors often review this figure alongside Conduit Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, CDT's gross profit moved from $1.4B to $1.1B — a 22.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Conduit Pharmaceuticals's operating scale or balance-sheet position.

Against its sector companies, CDT currently prints $1.1B for gross profit, while the sector average sits near $760M. That is roughly 42.8% above the sector mean. Large gaps often invite a closer look at Conduit Pharmaceuticals's growth, margins, and balance sheet.

A gross profit figure of $1.1B for CDT is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $760M. Explore the charts below for those layers of context.

After noting CDT's gross profit ($1.1B), review year-over-year change from $1.4B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.